|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IFT20 |
Gene summary for IFT20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IFT20 | Gene ID | 90410 |
| Gene name | intraflagellar transport 20 | |
| Gene Alias | IFT20 | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8IY31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90410 | IFT20 | GSM4909292 | Human | Breast | IDC | 1.58e-04 | 5.53e-01 | 0.1236 |
| 90410 | IFT20 | GSM4909293 | Human | Breast | IDC | 2.98e-05 | 2.69e-01 | 0.1581 |
| 90410 | IFT20 | GSM4909294 | Human | Breast | IDC | 6.27e-25 | 5.65e-01 | 0.2022 |
| 90410 | IFT20 | GSM4909296 | Human | Breast | IDC | 6.30e-07 | -1.57e-01 | 0.1524 |
| 90410 | IFT20 | GSM4909297 | Human | Breast | IDC | 2.14e-05 | -9.81e-02 | 0.1517 |
| 90410 | IFT20 | GSM4909311 | Human | Breast | IDC | 6.55e-19 | -1.77e-01 | 0.1534 |
| 90410 | IFT20 | GSM4909312 | Human | Breast | IDC | 1.35e-05 | -3.40e-02 | 0.1552 |
| 90410 | IFT20 | GSM4909313 | Human | Breast | IDC | 2.26e-02 | -6.24e-02 | 0.0391 |
| 90410 | IFT20 | GSM4909316 | Human | Breast | IDC | 5.34e-07 | 2.15e-01 | 0.21 |
| 90410 | IFT20 | GSM4909319 | Human | Breast | IDC | 2.82e-23 | -1.31e-01 | 0.1563 |
| 90410 | IFT20 | GSM4909320 | Human | Breast | IDC | 1.06e-02 | -2.28e-01 | 0.1575 |
| 90410 | IFT20 | GSM4909321 | Human | Breast | IDC | 5.08e-08 | -1.04e-01 | 0.1559 |
| 90410 | IFT20 | NCCBC14 | Human | Breast | DCIS | 5.64e-06 | 6.76e-02 | 0.2021 |
| 90410 | IFT20 | NCCBC5 | Human | Breast | DCIS | 9.16e-15 | 2.05e-01 | 0.2046 |
| 90410 | IFT20 | P1 | Human | Breast | IDC | 2.96e-10 | -1.01e-01 | 0.1527 |
| 90410 | IFT20 | DCIS2 | Human | Breast | DCIS | 3.17e-36 | 1.18e-01 | 0.0085 |
| 90410 | IFT20 | LZE2T | Human | Esophagus | ESCC | 2.79e-02 | 5.09e-01 | 0.082 |
| 90410 | IFT20 | LZE4T | Human | Esophagus | ESCC | 2.67e-08 | 1.92e-01 | 0.0811 |
| 90410 | IFT20 | LZE5T | Human | Esophagus | ESCC | 1.83e-02 | 3.22e-01 | 0.0514 |
| 90410 | IFT20 | LZE7T | Human | Esophagus | ESCC | 5.88e-04 | 1.91e-01 | 0.0667 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006053714 | Prostate | Tumor | muscle tissue development | 107/3246 | 403/18723 | 1.93e-06 | 3.34e-05 | 107 |
| GO:000165513 | Prostate | Tumor | urogenital system development | 90/3246 | 338/18723 | 1.08e-05 | 1.56e-04 | 90 |
| GO:003001015 | Prostate | Tumor | establishment of cell polarity | 46/3246 | 143/18723 | 1.09e-05 | 1.56e-04 | 46 |
| GO:009016214 | Prostate | Tumor | establishment of epithelial cell polarity | 16/3246 | 31/18723 | 1.38e-05 | 1.89e-04 | 16 |
| GO:001097011 | Prostate | Tumor | transport along microtubule | 48/3246 | 155/18723 | 2.20e-05 | 2.80e-04 | 48 |
| GO:003406712 | Prostate | Tumor | protein localization to Golgi apparatus | 15/3246 | 29/18723 | 2.48e-05 | 3.10e-04 | 15 |
| GO:001470613 | Prostate | Tumor | striated muscle tissue development | 98/3246 | 384/18723 | 2.96e-05 | 3.56e-04 | 98 |
| GO:000931415 | Prostate | Tumor | response to radiation | 109/3246 | 456/18723 | 1.94e-04 | 1.70e-03 | 109 |
| GO:003150312 | Prostate | Tumor | protein-containing complex localization | 59/3246 | 220/18723 | 2.71e-04 | 2.24e-03 | 59 |
| GO:006049115 | Prostate | Tumor | regulation of cell projection assembly | 52/3246 | 188/18723 | 2.71e-04 | 2.24e-03 | 52 |
| GO:004269213 | Prostate | Tumor | muscle cell differentiation | 93/3246 | 384/18723 | 3.45e-04 | 2.73e-03 | 93 |
| GO:000182213 | Prostate | Tumor | kidney development | 74/3246 | 293/18723 | 3.68e-04 | 2.87e-03 | 74 |
| GO:012003215 | Prostate | Tumor | regulation of plasma membrane bounded cell projection assembly | 51/3246 | 186/18723 | 3.87e-04 | 2.99e-03 | 51 |
| GO:190211512 | Prostate | Tumor | regulation of organelle assembly | 51/3246 | 186/18723 | 3.87e-04 | 2.99e-03 | 51 |
| GO:007200113 | Prostate | Tumor | renal system development | 75/3246 | 302/18723 | 5.74e-04 | 4.13e-03 | 75 |
| GO:006184213 | Prostate | Tumor | microtubule organizing center localization | 14/3246 | 33/18723 | 6.47e-04 | 4.60e-03 | 14 |
| GO:00991111 | Prostate | Tumor | microtubule-based transport | 51/3246 | 190/18723 | 6.62e-04 | 4.68e-03 | 51 |
| GO:00350511 | Prostate | Tumor | cardiocyte differentiation | 43/3246 | 156/18723 | 9.45e-04 | 6.20e-03 | 43 |
| GO:003085911 | Prostate | Tumor | polarized epithelial cell differentiation | 11/3246 | 24/18723 | 1.13e-03 | 7.23e-03 | 11 |
| GO:005114614 | Prostate | Tumor | striated muscle cell differentiation | 69/3246 | 283/18723 | 1.56e-03 | 9.54e-03 | 69 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IFT20 | SNV | Missense_Mutation | c.152N>T | p.Glu51Val | p.E51V | Q8IY31 | protein_coding | deleterious(0.01) | probably_damaging(0.914) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
| IFT20 | insertion | In_Frame_Ins | novel | c.190_191insTGAAAGGGTCCACGAAGTTGGCTGGCTCTCTGAAAG | p.Lys64delinsMetLysGlySerThrLysLeuAlaGlySerLeuLysGlu | p.K64delinsMKGSTKLAGSLKE | Q8IY31 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| IFT20 | SNV | Missense_Mutation | novel | c.247N>T | p.Leu83Phe | p.L83F | Q8IY31 | protein_coding | deleterious(0.01) | possibly_damaging(0.51) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IFT20 | SNV | Missense_Mutation | c.341N>A | p.Ala114Asp | p.A114D | Q8IY31 | protein_coding | tolerated(0.05) | possibly_damaging(0.857) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IFT20 | SNV | Missense_Mutation | rs372746932 | c.401N>A | p.Arg134Gln | p.R134Q | Q8IY31 | protein_coding | tolerated(0.11) | benign(0.169) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| IFT20 | SNV | Missense_Mutation | novel | c.80N>C | p.Met27Thr | p.M27T | Q8IY31 | protein_coding | deleterious(0) | benign(0.023) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IFT20 | SNV | Missense_Mutation | novel | c.81N>A | p.Met27Ile | p.M27I | Q8IY31 | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-86-7954-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| IFT20 | SNV | Missense_Mutation | novel | c.281A>G | p.Glu94Gly | p.E94G | Q8IY31 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |